Search research articles
Contact Us
Filters
Showing results (221-230 of 264) with videos related to
Page
of 27
Sort By:
Journal of Hematology & Oncology
|
February 24, 2017
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Haematologica
|
January 25, 2015
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Blood
|
March 6, 2002
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
Moshe Talpaz, Richard T Silver, Brian J Druker, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 15, 2015
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms
Brady L Stein, Jason Gotlib, Murat Arcasoy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2023
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, et al.
Leukemia
|
April 9, 2025
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1<sup>T315I</sup> treated with at least 2 prior TKIs: Phase 1 final results
Andreas Hochhaus, Dong-Wook Kim, Jorge E Cortes, et al.
Leukemia
|
May 16, 2024
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results
Jorge E Cortes, Koji Sasaki, Dong-Wook Kim, et al.
Nature Communications
|
June 29, 2022
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma
Josh N Vo, Yi-Mi Wu, Jeanmarie Mishler, et al.
British Journal of Haematology
|
March 14, 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
The Lancet. Oncology
|
April 17, 2016
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
Jeffrey H Lipton, Charles Chuah, Agnès Guerci-Bresler, et al.
Page
of 27
Search research articles
Search
Showing results (221-230 of 264) with videos related to
Sort By:
Page
of 27
Journal of Hematology & Oncology
|
February 24, 2017
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Haematologica
|
January 25, 2015
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Blood
|
March 6, 2002
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
Moshe Talpaz, Richard T Silver, Brian J Druker, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 15, 2015
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms
Brady L Stein, Jason Gotlib, Murat Arcasoy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2023
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, et al.
Leukemia
|
April 9, 2025
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1<sup>T315I</sup> treated with at least 2 prior TKIs: Phase 1 final results
Andreas Hochhaus, Dong-Wook Kim, Jorge E Cortes, et al.
Leukemia
|
May 16, 2024
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results
Jorge E Cortes, Koji Sasaki, Dong-Wook Kim, et al.
Nature Communications
|
June 29, 2022
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma
Josh N Vo, Yi-Mi Wu, Jeanmarie Mishler, et al.
British Journal of Haematology
|
March 14, 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
The Lancet. Oncology
|
April 17, 2016
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
Jeffrey H Lipton, Charles Chuah, Agnès Guerci-Bresler, et al.
Page
of 27